Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorEl-Khoueiry, A. (Anthony)-
dc.creatorTrojan, J. (Jörg)-
dc.creatorMeyer, T. (Tim)-
dc.creatorYau, T. (Thomas)-
dc.creatorMelero, I. (Ignacio)-
dc.creatorKudo, M. (Masatoshi)-
dc.creatorHsu, C. (Chiun)-
dc.creatorKim, T.Y. (Tae-You)-
dc.creatorChoo, S.P. (Su-Pin)-
dc.creatorKang, Y.K. (Yoon-Koo)-
dc.creatorYeo, W. (W.)-
dc.creatorChopra, A. (A.)-
dc.creatorSoleymani, S. (S.)-
dc.creatorYao, J. (J.)-
dc.creatorNeely, J. (Jaclyn)-
dc.creatorTschaika, M. (Marina)-
dc.creatorWelling, T.H. (T. H.)-
dc.creatorSangro, B. (Bruno)-
dc.date.accessioned2024-02-01T10:46:18Z-
dc.date.available2024-02-01T10:46:18Z-
dc.date.issued2023-
dc.identifier.citationEl-Khoueiry, A. (Anthony); Trojan, J. (Jörg); Meyer, T. (Tim); et al. "Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040". Annals of Oncology. S0923-7534 (23), 2023, 05115-3es_ES
dc.identifier.issn0923-7534-
dc.identifier.urihttps://hdl.handle.net/10171/68695-
dc.description.abstractBackground: Patients with advanced hepatocellular carcinoma (aHCC) have a poor prognosis and high mortality. Nivolumab monotherapy demonstrated clinical benefit with an acceptable safety profile in patients with aHCC in the CheckMate 040 study. Five-year follow-up of the sorafenib-naive and sorafenib-experienced cohorts of CheckMate 040 are presented here. Patients and methods: Patients received nivolumab monotherapy at dose levels of 0.1-10.0 mg/kg (dose-escalation phase) or 3 mg/kg (dose-expansion phase) every 2 weeks until disease progression or unacceptable toxicity. Primary endpoints were safety and tolerability (dose escalation), and objective response rate (ORR) by blinded independent central review (BICR) and by investigator per RECIST version 1.1 (dose expansion). Results: Eighty sorafenib-naive and 154 sorafenib-experienced patients were treated. Minimum follow-up in both groups was 60 months. ORR per BICR was 20% (95% CI 12-30) and 14% (95% CI 9-21) in the sorafenib-naive and sorafenib-experienced groups, respectively. Responses occurred regardless of HCC etiology or baseline tumor cell programmed death ligand 1 (PD-L1) expression levels. Median overall survival (OS) was 26.6 months (95% CI 16.6-30.6) and 15.1 months (95% CI 13.0-18.2) in sorafenib-naive and sorafenib-experienced patients, respectively. The 3-year OS rates were 28% in the sorafenib-naive and 20% in the sorafenib-experienced group; 5-year OS rates were 14% and 12%, respectively. No new safety signals were identified; grade 3/4 treatment-related adverse events were observed in 33% and 21% in the sorafenib-naive and sorafenib-experienced patients, respectively. Biomarker analyses showed that baseline PD-L1 expression ≥1% was associated with higher ORR and longer OS compared with PD-L1 <1%. In the sorafenib-naive group, patients with OS ≥3 years exhibited higher baseline CD8 T-cell density compared with those with OS <1 year. Conclusion: With 5 years of follow-up, nivolumab monotherapy continued to provide durable clinical benefit with manageable safety in sorafenib-naive and sorafenib-experienced patients with aHCC.es_ES
dc.description.sponsorshipThe study was supported by Bristol Myers Squibb.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectAdvanced hepatocellular carcinomaes_ES
dc.subjectCheckpoint inhibitores_ES
dc.subjectNivolumabes_ES
dc.subjectSorafenibes_ES
dc.titleNivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteCC BY-NC-NDes_ES
dc.identifier.doi10.1016/j.annonc.2023.12.008-
dadun.citation.number23es_ES
dadun.citation.publicationNameAnnals of Oncologyes_ES
dadun.citation.startingPage05115-3es_ES
dadun.citation.volumeS0923-7534es_ES
dc.identifier.pmid38151184-

Ficheros en este ítem:
Vista previa
Fichero
Ann Oncol. 2023 (23)05115-3.-1.pdf
Descripción
Tamaño
1.02 MB
Formato
Adobe PDF


Estadísticas e impacto
0 citas en
0 citas en

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.